Developmental Therapeutics Research Program

发育治疗研究计划

• 批准号: 10628432
• 负责人: Anthony Charles Faber
• 金额: $ 6.34万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-12-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628432
• 关键词: Address; Adult; African American; Antineoplastic Agents; Area; Automobile Driving; Basic Science; Biological Products; Black race; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Catchment Area; Clinic; Clinical Cancer Center; Clinical Investigator; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Community Clinical Oncology Program; Country; Critiques; Dedications; Development; Developmental Therapeutics Program; Diagnosis; Disease; Disparity; Doctor of Philosophy; Drug Combinations; Endometrial Carcinoma; Enrollment; Ethnic Origin; Evaluation; Foundations; Funding; Goals; Hematologic Neoplasms; Immune Targeting; Immunologist; Immunotherapy; Industry; Infrastructure; Institution; Intervention; Investigational Therapies; Investments; Journals; Laboratories; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Medicine; Minority; Minority Enrollment; Minority Recruitment; Monitor; Monitoring Clinical Trials; National Cancer Institute; National Clinical Trials Network; Nature; Patients; Peer Review; Pharmaceutical Preparations; Pharmacodynamics; Phase; Protocols documentation; Publications; Publishing; Race; Recurrence; Regimen; Reporting; Research; Research Personnel; Research Priority; Schools; Science; Scientist; Signal Pathway; Strategic Planning; System; Therapeutic; Therapeutic Research; Translating; Translational Research; Translations; Underrepresented Minority; United States National Institutes of Health; Universities; Validation; Virginia; Woman; Work; biomarker identification; cancer cell; cancer prevention; cancer therapy; college; community center; design; disparity gap; drug development; drug discovery; early phase trial; improved; malignant breast neoplasm; member; new therapeutic target; novel; novel therapeutics; pediatric patients; pre-clinical; precision medicine; programs; rational design; response; rural patients; small molecule; therapeutically effective; therapy development; therapy resistant; translational clinical trial; treatment disparity; treatment trial; tumor; working group

DEVELOPMENTAL THERAPEUTICS PROGRAM: PROJECT SUMMARY The Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) Developmental Therapeutics (DT) Program’s overarching goals are to leverage MCC basic and translational science to discover, develop, and evaluate novel MCC-conceived small molecules and biologics for application in improved strategies for cancer treatments and to drive MCC’s efforts in leading and participating in national and local clinical trial efforts. Guided by the 2021-2025 MCC Strategic Plan, 51 members of the DT Program, representing 15 departments and four VCU Schools/Colleges, lead efforts in drug discovery and development, designing rational drug combination regimens to overcome therapeutic resistance, and evaluating the very latest and most promising therapeutic approaches through clinical trials. DT members currently hold $7.1M in annual, direct, peer-reviewed funding ($3.5M from National Cancer Institute (NCI); $1.3M from other National Institutes of Health; $2.2M from other agencies) and another $1.1M from industry and foundation agencies. Notably, NCI funding has increased by 75% compared to the last Cancer Center Support Grant renewal in 2016. In the current project period, members have published their scientific results in 410 cancer-focused research articles reporting their discoveries and observations. Demonstrating the program’s highly collaborative nature, 123 (30%) publications were intra- programmatic and 154 (38%) were inter-programmatic with scientists in MCC’s Cancer Biology and Cancer Prevention and Control Programs. In total, 258 (63%) of these publications were in collaboration with other institutions including other NCI-designated cancer centers, and 64 (16%) were in high-impact (IF>10) biomedical science journals. Most importantly, members of the DT Program work with the MCC Clinical Trials Office and the Center’s 14 Disease Working Groups in conjunction with the Protocol Review and Monitoring System to initiate, execute, and monitor clinical trials. In 2021, there were 153 interventional treatment trials for adult and pediatric patients actively accruing (15 investigator-initiated, 91 National Clinical Trials Network, 11 Experimental Therapeutics Clinical Trials Network (ETCTN), and 36 industry-initiated). Since 2016, MCC clinical investigators have enrolled 1,000 patients to treatment trials. Importantly, as one of 14 Minority/Underserved NCI Community Oncology Research Program designated institutions, the DT Program largely contributes to MCC’s high enrollment of minorities (34%) onto treatment trials. The MCC was also invited to join the ETCTN through the Princess Margaret Cancer Center’s Lead Academic Organization in 2016, as a result of its demonstrated capabilities to develop and perform early phase trials. Another important initiative within the DT Program this project period has been the 2018 launch of a Molecules to Medicine (M2M) initiative. With significant MCC leadership facilitation and investment there are more than a dozen efforts to translate novel agents discovered and/or developed by MCC members across the translational continuum – from target identification/validation all the way through the preparatory stages for early phase trials.

发展治疗项目：项目摘要 弗吉尼亚联邦大学(VCU)梅西癌症中心(MCC)发展治疗(DT) 该计划的首要目标是利用MCC基础科学和翻译科学来发现、开发和 评估新型MCC构思的小分子和生物制品在癌症改进策略中的应用 并推动MCC在领导和参与国家和地方临床试验方面的努力。引导式 到2021-2025年MCC战略计划，DT方案的51名成员，代表15个部门和4个 VCU学校/学院，领导药物发现和开发，设计合理的药物组合 克服治疗耐药性的方案，并评估最新和最有希望的治疗方法 通过临床试验的方法。DT成员目前持有710万美元的年度、直接、同行评审资金 (350万美元来自国家癌症研究所(NCI)；130万美元来自其他国家卫生研究院；220万美元来自其他 另外还有来自行业和基金会机构的110万美元。值得注意的是，NCI的资金增加了 与2016年上一次癌症中心支持拨款续签相比，增长了75%。在当前项目期内，成员 已经在410篇以癌症为重点的研究文章中发表了他们的科学成果，报告了他们的发现和 观察。123(30%)的出版物是内部的，这表明了该计划的高度协作性 项目和154名(38%)与MCC的癌症生物学和癌症的科学家进行项目间的项目 预防和控制程序。总体而言，这些出版物中有258份(63%)是与其他 包括国家癌症研究所指定的其他癌症中心和(16%)在内的机构处于高影响力(IF&GT；10)生物医学 科学期刊。最重要的是，DT计划的成员与MCC临床试验办公室和 该中心的14个疾病工作组与礼宾审查和监测系统相结合，以 启动、执行和监测临床试验。2021年，有153项成人和老年人介入治疗试验 儿科患者积极积累(15名研究人员发起，91项国家临床试验网络，11项实验 治疗临床试验网络(ETCTN)，36个行业发起)。自2016年以来，MCC临床研究人员 已经招募了1,000名患者参加治疗试验。重要的是，作为14个少数民族/服务不足的NCI社区之一 肿瘤学研究计划指定机构，DT计划在很大程度上促进了MCC的高 少数民族(34%)参加治疗试验。管委会亦获邀透过 玛格丽特公主癌症中心2016年的主要学术组织，其展示的 开发和执行早期试验的能力。DT计划中的另一项重要倡议 项目期间已于2018年启动了一项分子到医学(M2M)倡议。具有显著的MCC 领导力、便利化和投资有十多项努力翻译新奇特工发现 和/或由MCC成员在整个翻译连续体中开发-从目标识别/验证全部 通过前期试验的准备阶段的方法。